143 related articles for article (PubMed ID: 3287749)
41. Comparative study of aztreonam and cefamandole in the treatment of serious urinary tract infections.
Tsouroutsoglou W; Sion ML; Stathopoulos GA; Kapoulas S; El-Messidi M; Paradelis AG
Methods Find Exp Clin Pharmacol; 1983; 5(6):385-90. PubMed ID: 6684719
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness and tolerability of aztreonam in urinary tract infection caused by multiresistant bacteria.
Muzzonigro G; Minardi D; Caraceni E; Villanova A; Polito M
Acta Urol Belg; 1987; 55(3):485-90. PubMed ID: 3661329
[No Abstract] [Full Text] [Related]
43. The role of aztreonam in treatment of complicated urinary tract infections in children.
Kline MW
Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S113-6; discussion S128-32. PubMed ID: 2682509
[TBL] [Abstract][Full Text] [Related]
44. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
Swabb EA; Jenkins SA; Muir JG
Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
[TBL] [Abstract][Full Text] [Related]
45. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria.
Cox CE
Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335
[TBL] [Abstract][Full Text] [Related]
46. [Prophylaxis in prostatic surgery with aztreonam. Our experience].
Moyano Calvo JL; Arellano Gañán R; Sempere Gutiérrez A; Sanz Sacristán J; Teba del Pino F; Melón Rey FJ; Herrero Torres L; Pereira Sanz I
Arch Esp Urol; 1992; 45(6):519-21. PubMed ID: 1510489
[TBL] [Abstract][Full Text] [Related]
47. Importance of urinary tract infection to antibiotic use among hospitalized patients.
Gandhi T; Flanders SA; Markovitz E; Saint S; Kaul DR
Infect Control Hosp Epidemiol; 2009 Feb; 30(2):193-5. PubMed ID: 19125678
[TBL] [Abstract][Full Text] [Related]
48. Aztreonam in the treatment of urinary tract infection.
Childs SJ
Am J Med; 1985 Feb; 78(2A):44-6. PubMed ID: 3881948
[TBL] [Abstract][Full Text] [Related]
49. Aztreonam in the treatment of urinary tract infections: a multicenter trial.
Martelli A; Cortecchia V; Ventriglia L
Chemotherapy; 1989; 35 Suppl 1():8-14. PubMed ID: 2659294
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Fayed DF; Dahmash NS; Saddique AA; Shibl AM
J Chemother; 1992 Jun; 4(3):167-70. PubMed ID: 1517810
[TBL] [Abstract][Full Text] [Related]
51. Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
Cook JL
Am J Med; 1990 Mar; 88(3C):34S-37S; discussion 38S-42S. PubMed ID: 2316557
[TBL] [Abstract][Full Text] [Related]
52. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
Rabinad E; Bosch-Perez A
Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
[TBL] [Abstract][Full Text] [Related]
53. The clinical use of aztreonam.
Schönwald S; Schoss-Vidensek Z; Car V; Krznar B
Chemotherapy; 1989; 35 Suppl 1():45-8. PubMed ID: 2731450
[TBL] [Abstract][Full Text] [Related]
54. Cephazloin sodium - an invivo and in vitro evaluation of 100 patients with urinary tract infections.
Rimmer DM
Scott Med J; 1976 Sep; 20(5):259-60. PubMed ID: 1265476
[TBL] [Abstract][Full Text] [Related]
55. Increasing resistance against antibiotics in bacteria isolated from the lower urinary tract of an outpatient population of spinal cord injury patients.
Hinkel A; Finke W; Bötel U; Gatermann SG; Pannek J
Urol Int; 2004; 73(2):143-8. PubMed ID: 15331899
[TBL] [Abstract][Full Text] [Related]
56. Aztreonam.
Cunha BA
Urology; 1993 Mar; 41(3):249-58. PubMed ID: 8442309
[TBL] [Abstract][Full Text] [Related]
57. Clinical experience with aztreonam in four Mediterranean countries.
Daikos GK
Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
[TBL] [Abstract][Full Text] [Related]
58. [The role of stagnancy of urinary flow in causing urinary tract infection].
Arakawa S; Nakata K; Kamidono S
Hinyokika Kiyo; 1991 Sep; 37(9):957-62. PubMed ID: 1785420
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
Naber KG; Dette GA; Kees F; Knothe H; Grobecker H
J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
[TBL] [Abstract][Full Text] [Related]
60. [An Italian multicenter study on the efficacy and tolerability of aztreonam in the treatment of urinary tract infections].
Martelli A; Cortecchia V; Ventriglia L
Clin Ter; 1988 May; 125(3):191-201. PubMed ID: 2973940
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
